Generation Lab says it has begun administering a weekly injection made from two existing drugs to make the body’s systemic environment younger. The company calls the treatment 1 Generation. It has publicized reports of more energy, stronger grip, better vision, improved exercise capacity and other changes among a small group of insiders.
Those claims deserve attention for two reasons. First, Generation Lab was co-founded by Irina Conboy, a respected aging researcher whose work helped show that the bloodstream can influence how old tissues repair themselves. Second, the evidence needed to judge this specific treatment is still missing. The drug identities are secret, no controlled human results have been published, and no registered trial of the combination could be located as of August 28, 2026.
The biology is interesting. The current human claim is unproven.
The claim
Generation Lab describes 1 Generation as an injectable combination of two already approved drugs. According to a company fact sheet reported by MIT Technology Review, the treatment is intended to block the systemic spread of aging, reactivate repair mechanisms and restore more youthful function across multiple tissues.
The company has not disclosed which two drugs it is using. Chief executive Alina Su told the publication that secrecy is intended to deter imitators. That decision makes independent evaluation nearly impossible. Without the drug names, outside researchers and physicians cannot assess whether the proposed mechanism is plausible, whether the dose is supported, or what interactions and contraindications may matter.
Using an approved drug for a purpose or population not listed in its regulatory approval is called off-label use. Physicians can legally prescribe drugs off label in the United States, but that does not mean the Food and Drug Administration has found the new use safe or effective. A combination of two approved drugs is not automatically a validated treatment, especially when the combination and intended anti-aging use have not been publicly tested.
Where the idea comes from
Conboy’s earlier research helped establish that aging is influenced by signals circulating through the body. In a landmark 2005 Nature study, researchers surgically joined the circulatory systems of young and old mice, a technique called heterochronic parabiosis. Exposure to the shared circulation restored aspects of muscle stem-cell activation and repair in old mice.
Parabiosis is often reduced to a story about young blood. That is misleading. Joined animals share a complex physiological system that can alter hormones, immune signals, organ function and the removal of circulating molecules. The experiment showed that the systemic environment matters. It did not establish that a particular component of young blood reverses aging in humans.
Later work from Conboy and colleagues suggested that removing age-elevated factors may be as important as adding youthful ones. In a 2020 mouse study, researchers replaced about half of old animals’ plasma with saline and albumin. Measures in muscle, liver and brain shifted in a more youthful direction even though no young plasma was added.
Human plasma-exchange studies have since reported changes in proteins, immune measures and biological-age biomarkers. A 2025 randomized study in 42 adults over age 50 found changes in several aging clocks after therapeutic plasma exchange. The study did not show that participants lived longer or avoided disease. For more context, see our earlier Hype Check, Young Blood Reverses Aging: What the Plasma Experiments Really Show.
A 2026 Nature Biomedical Engineering study also found that old human serum could induce aging-associated changes in laboratory-grown liver and fat microtissues. That system may help researchers test circulating signals under controlled conditions. It is a cell model, not evidence that changing a person’s blood with two drugs produces whole-body rejuvenation.
What has actually been tested in humans
According to MIT Technology Review, the people who have received 1 Generation include Conboy, Su, company co-founder Michael Suswal and physician Matt Cook, along with a handful of other insiders. The company has not provided a complete participant count, a protocol, or baseline and follow-up data suitable for independent analysis.
Generation Lab circulated a spreadsheet describing changes among recipients. The reported observations included improved vision in a 64-year-old woman, longer landscaping sessions in a 59-year-old man, more badminton, greater hand-grip strength, increased bowel movements and improved sexual function. Conboy reported more energy, while Cook described better mental clarity and fewer aches.
These reports range from subjective impressions to potentially measurable functions, but the public material does not show a controlled experiment. There is no disclosed comparison group, random assignment, blinding, predefined endpoint or complete accounting of adverse events. Expectations, day-to-day variation, changes in other treatments and selective reporting could all influence the result.
No peer-reviewed paper currently demonstrates that 1 Generation rejuvenates humans. Searches of ClinicalTrials.gov did not identify a registered trial matching the undisclosed two-drug treatment. The company says a larger study involving more than 100 people is planned. The publication later corrected its report to clarify that Generation Lab says participation in that trial will be free and company-sponsored, although people may separately pay a physician to receive the treatment outside the trial.
The missing pieces
A credible test would disclose the drugs, doses, eligibility rules, monitoring plan and rationale before results are known. It would register the protocol, use a placebo or suitable comparison group, track harms as carefully as benefits, and report all predefined outcomes.
The endpoints also matter. A short-term change in grip strength or a biological-age score is not the same as slowing aging. Biomarkers can be useful if they reliably predict future health and respond in ways that reflect meaningful benefit. Many aging clocks and molecular panels have not yet been validated as surrogate endpoints for living longer or remaining free of disease.
Functional outcomes can be more tangible, but they still require controls and standardized measurement. Better exercise capacity could reflect training, motivation, pain relief or an ordinary good day. Improved vision would require appropriate eye testing. Claims of systemic rejuvenation would demand evidence across multiple systems, durability after treatment and a safety record large enough to detect uncommon problems.
Drug secrecy is an especially large obstacle. Outside experts cannot evaluate the pharmacology, and prospective patients cannot make a fully informed assessment of risks. It also prevents other laboratories from attempting replication, which is a basic route from intriguing result to reliable knowledge.
Could the underlying biology still be important?
Yes. The evidence that circulating signals influence repair, inflammation and metabolism is substantial enough to justify continued research. A targeted drug that suppresses a harmful age-elevated factor or restores a disrupted signaling pathway could ultimately be safer and more practical than exchanging plasma.
That possibility is why Generation Lab’s work should be judged by evidence rather than dismissed by association with exaggerated young-blood marketing. The company’s scientific premise can be plausible while its public claims remain far ahead of its data.
A well-designed trial could move the discussion forward even if it finds only a modest effect or none at all. Disclosing the intervention and publishing complete results would let researchers distinguish a genuine therapeutic signal from anecdote.
The Lifespan Brief verdict
Circulating biology is a credible part of aging research. Generation Lab has not yet shown that its secret two-drug injection makes people biologically younger.
The current human evidence consists of uncontrolled observations from a small, incompletely described group with close ties to the company. No peer-reviewed human trial, public protocol or matching trial registration establishes rejuvenation, improved healthspan or longer life.
1 Generation may eventually produce a testable and useful result. For now, the strength of the claim is much greater than the strength of the evidence.
This article is for general information and is not personal medical advice.
Sources
MIT Technology Review investigation and company responses, August 27, 2026.
Nature: Rejuvenation of aged progenitor cells by exposure to a young systemic environment, 2005.
Aging: Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin, 2020.
Aging Cell: randomized therapeutic plasma exchange study, 2025.
Nature Biomedical Engineering: human microphysiological systems of aging, 2026.